T cell therapy for nasopharyngeal carcinoma

Journal of Cancer

Volumn 2, Issue 1, 2011, Pages 341-346

  Basso, S ^a   Zecca, M ^a   Merli, P ^a   Gurrado, A ^a   Secondino, S ^a   Quartuccio, G ^a   Guido, I ^a   Guerini, P ^a   Ottonello, G ^a   Zavras, N ^a   Maccario, R ^a   Pedrazzoli, P ^a   Comoli, P ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Cytotoxic T lymphocytes; Epstein Barr virus; Nasopharyngeal carcinoma; T cell therapy

Indexed keywords

RECOMBINANT INTERLEUKIN 2;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CELL THERAPY; CYTOTOXIC T LYMPHOCYTE; EPSTEIN BARR VIRUS; HUMAN; LOW DRUG DOSE; NASOPHARYNX CARCINOMA; NONHUMAN;

EID: 84856506061     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.2.341     Document Type: Article

References (55)

1. Rosenberg SA, Restifo NP, Yang JC, et al. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer. 2008; 8: 299-308.
2. Blattman JN, Greenberg PD. Cancer immunotherapy: a treat-ment for the masses. Science. 2004; 305: 200-5.
3. Leen AM, Rooney CM, Foster AE. Improving T cell therapy for cancer. Annu Rev Immunol. 2007; 25: 243-65.
4. Rosenberg SA, Lotze MT, Muul LM, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with met-astatic cancer. N Engl J Med. 1985; 313: 1485-92.
5. Sangiolo D, Mesiano G, Carnevale-Schianca F, et al. Cytokine induced killer cells as adoptive immunotherapy strategy to augment graft versus tumor after hematopoietic cell trans-plantation. Expert Opin Biol Ther. 2009 Jul;9(7):831-40.
6. Rosenberg SA, Packard BS, Aebersold PM, et al. Use of tu-mor-infiltrating lymphocytes and interleukin-2 in the immu-notherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med. 1988; 319: 1676-80.
7. Dudley ME, Yang JC, Sherry R, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol. 2008; 26: 5233-9.
8. Shablak A, Hawkins RE, Rothwell DG, Elkord E. T cell-based immunotherapy of metastatic renal cell carcinoma: modest success and future perspective. Clin Cancer Res 2009;15:6503-10.
9. Heslop HE, Slobod KS, Pule MA, Hale GA, Rousseau A, Smith CA, et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 2010; 115:925-935.
10. Comoli P, Labirio M, Basso S, et al. Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for preven-tion of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication. Blood. 2002; 99: 2592-8.
11. Haque T, Wilkie GM, Jones MM, Higgins CD, Urquhart G, Wingate P, et al. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood 2007; 110:1123-1131.
12. Spano JP, Busson P, Atlan D, et al. Nasopharyngeal carcinomas: an update. Eur J Cancer. 2003; 39: 2121-35.
13. Tao Q, Chan AT. Nasopharyngeal carcinoma: molecular path-ogenesis and therapeutic developments. Expert Rev Mol Med. 2007; 9: 1-24.
14. Ayan I, Kaytan E, Ayan N. Childhood nasopharyngeal carci-noma: from biology to treatment. Lancet Oncol. 2003; 4: 13-21.
15. Williams H, Crawford DH. Epstein-Barr virus: the impact of scientific advances on clinical practice. Blood. 2006; 107: 862-9.
16. Roebuck, DJ. Skeletal complications in pediatric oncology pa-tients. Radiographics. 1999; 19: 873-85.
17. Bass IS, Haller JO, Berdon WE, et al. Nasopharyngeal carcino-ma: clinical and radiographic findings in children. Radiology. 1985; 156: 651-4.
18. Cvitkovic E, Bachouchi M, Boussen H, et al. Leukemoid reaction, bone marrow invasion, fever of unknown origin, and metastatic pattern in the natural history of advanced undiffer-entiated carcinoma of nasopharyngeal type: a review of 255 consecutive cases. J Clin Oncol. 1993; 11: 2434-42.
19. Perez CA, Devineni VR, Marcial-Vega V, et al. Carcinoma of the nasopharynx: factors affecting prognosis. Int J Radiat Oncol Bi-ol Phys. 1992; 23: 271-80.
20. Ozyar E, Selek U, Laskar S, et al. Treatment results of 165 pedi-atric patients with non-metastatic nasopharyngeal carcinoma: a Rare Cancer Network study. Radiother Oncol. 2006; 81: 39-46.
21. Orbach D, Brisse H, Helfre S, et al. Radiation and chemotherapy combination for nasopharyngeal carcinoma in children: Radi-otherapy dose adaptation after chemotherapy response to minimize late effects. Pediatr Blood Cancer. 2008; 50: 849-53.
22. Wolden SL, Zelefsky MJ, Hunt MA, et al. Failure of a 3D con-formal boost to improve radiotherapy for nasopharyngeal car-cinoma. Int J Radiat Oncol Biol Phys. 2001; 49: 1229-34.
23. Lee N, Xia P, Quivey JM, et al. Intensity-modulated radiother-apy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience. Int J Radiat Oncol Biol Phys. 2002; 53: 12-22.
24. Hsiung CY, Yorke ED, Chui CS, et al. Intensity-modulated radiotherapy versus conventional three-dimensional conformal radiotherapy for boost or salvage treatment of nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2002; 53: 638-47.
25. Song CH, Wu HG, Heo DS, et al. Treatment outcomes for radi-otherapy alone are comparable with neoadjuvant chemother-apy followed by radiotherapy in early-stage nasopharyngeal carcinoma. Laryngoscope. 2008; 118: 663-70.
26. Al-Sarraf M, LeBlanc M, Giri PG, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol. 1998; 16: 1310-7.
27. Cheng SH, Tsai SY, Yen KL, et al. Concomitant radiotherapy and chemotherapy for early-stage nasopharyngeal carcinoma. J Clin Oncol. 2000; 18: 2040-5.
28. Langendijk JA, Leemans CR, Buter J, et al. The additional value of chemotherapy to radiotherapy in locally advanced naso-pharyngeal carcinoma: a meta-analysis of the published litera-ture. J Clin Oncol. 2004; 22: 4604-12.
29. Wei WJ, Sham JST. Nasopharyngeal carcinoma. Lancet 2005; 365: 2041-2054.
30. Chan AT, Hsu MM, Goh BC, et al. Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. J Clin On-col. 2005; 23:1-9.
31. Forastiere A, Koch W, Trotti A, et al. Head and neck cancer. N Engl J Med. 2001; 345: 1890-900.
32. Arango BA, Castrellon AB, Perez CA, et al. Nasopharyngeal carcinoma: alternative treatment options after disease progres-sion. Expert Rev Anticancer Ther. 2010; 10: 377-86.
33. Comoli P, Zecca M, Maccario R. Immunotherapy against EBV-lymphoma in recipients of HSCT. Expert Rev Hematol. 2010;3(5):625-632.
34. Merlo A, Turrini R, Dolcetti R, Martorelli D, Muraro E, Comoli P, Rosato A. The interplay between Epstein-Barr virus and the immune system: a rationale for adoptive cell therapy of EBV-related disorders. Haematologica. 2010; 95:1769-77.
35. Comoli P, Pedrazzoli P, Maccario R, et al. Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes. J Clin Oncol. 2005; 23: 8942-9.
36. Straathof KC, Bollard CM, Popat U, et al. Treatment of naso-pharyngeal carcinoma with Epstein-Barr virus--specific T lymphocytes. Blood. 2005; 105: 1898-904.
37. Louis CU, Straathof K, Bollard CM, et al. Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma. J Im-munother. 2010; 33: 983-90.
38. Louis CU, Straathof K, Bollard CM, et al. Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC pa-tients. Blood. 2009; 113: 2442-50.
39. Secondino S. et al. T-cell therapy for ebv-associated nasopha-ryngeal carcinoma: preparative lymphodepleting chemothera-py does not improve clinical results. Ann Oncol. 2011; in press.
40. Chua D, Huang J, Zheng B, et al. Adoptive transfer of autolo-gous Epstein-Barr virus-specific cytotoxic T cells for nasopha-ryngeal carcinoma. Int J Cancer. 2001; 94:73-80.
41. Comoli P, De Palma R, Siena S, et al. Adoptive transfer of al-logeneic EBV-specific cytotoxic T cells with in vitro antitumor activity boosts LMP-2-specific immune response in a patient with EBV-related nasopharyngeal carcinoma. Ann Oncol. 2004; 15:113-117.
42. Rosenberg SA, Dudley ME. Adoptive cell therapy for the treatment of patients wit.h metastatic melanoma. Curr Opin Immunol. 2009; 21: 233-40.
43. Dudley ME, Wunderlich JR, Yang JC, et al. Adoptive cell transfer therapy following nonmyeloablative but lym-phodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol. 2005;23:2346-2357.
44. Lee AW, et al. Retrospective analysis of patients with naso-pharyngeal carcinoma treated during 1976-1985: survival after local recurrence. Int J Radiat Oncol Biol Phys 1993; 26: 773-82.
45. Hasbini A, et al.. Phase II trial combining mitomycin with 5-fluorouracil, epirubicin, and cisplatin in recurrent and meta-static undifferentiated carcinoma of nasopharyngeal type. Ann Oncol, 1999; 10:421-5.
46. Yee C, Thompson JA, Byrd D, et al. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migra-tion, and antitumor effect of transferred T cells. Proc Natl Acad Sci U S A. 2002; 99: 16168-73.
47. Gottschalk S, Ng CY, Perez M, et al. An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative dis-ease unresponsive to therapy with virus-specific CTLs. Blood. 2001; 97: 835-43.
48. Gottschalk S, Edwards OL, Sili U, et al. Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies. Blood. 2003; 101: 1905-12.
49. Gahn B, Siller-Lopez F, Pirooz AD, et al. Adenoviral gene transfer into dendritic cells efficiently amplifies the immune response to LMP2A antigen: a potential treatment strategy for Epstein-Barr virus--positive Hodgkin's lymphoma. Int J Cancer. 2001; 93: 706-13.
50. Ranieri E, Herr W, Gambotto A, et al. Dendritic cells transduced with an adenovirus vector encoding Epstein-Barr virus latent membrane protein 2B: a new modality for vaccination. J Virol. 1999; 73: 10416-25.
51. Bollard CM, Gottschalk S, Leen AM, et al. Complete responses of relapsed lymphoma following genetic modification of tu-mor-antigen presenting cells and T-lymphocyte transfer. Blood. 2007; 110: 2838-45.
52. Drake CG, Jaffee E, Pardoll DM. Mechanisms of immune eva-sion by tumors. Adv Immunol. 2006;90:51-81.
53. Bollard CM, Rossig C, Calonge MJ, et al. Adapting a trans-forming growth factor beta-related tumor protection strategy to enhance antitumor immunity. Blood. 2002;99:3179-3187.
54. Savoldo B, Rooney CM, Di Stasi A, et al. Epstein Barr vi-rus-specific cytotoxic T lymphocytes expressing the anti-CD30 artificial chimeric T-cell receptor for immunotherapy of Hodg-kin disease. Blood. 2007;110:2620-2630.
55. Comoli P. Cell-based therapies: careful safety assessment for minimization of risk. Cytotherapy. 2010;12:710-2.